A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Active:	No
Cancer Type:	Breast Cancer Lung Cancer	NCT ID:	NCT03845166
Trial Phases:	Phase I	Protocol IDs:	XL092-001 (primary) NCI-2019-03738
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Exelixis Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT03845166

Summary

This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the
safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect
on biomarkers of XL092 administered alone, in combination with atezolizumab, and in
combination with avelumab to subjects with advanced solid tumors.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.